Evidence map›Paper›PMID 41509385›Full record

ArticlebioRxiv : the preprint server for biology2026

PRISM-Seq: An Ultra-sensitive Sequencing Approach For Mapping Lentiviral Integration Sites.

Virender Kumar Pal, Marie Canis, Emily Stone, Nathan L Board, Klara Lenart, Marcilio Jorge Fumagalli, Colin Kovas, R Brad Jones, Michel Nussenzweig, Frauke Muecksch and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Virender Kumar PalLaboratory of Retrovirology, The Rockefeller University, New York.ORCID 0000-0001-8378-1823
Marie CanisLaboratory of Retrovirology, The Rockefeller University, New York.
Emily StoneInfectious Diseases Division, Department of Medicine, Weill Cornell Medical College, New York.
Nathan L BoardInfectious Diseases Division, Department of Medicine, Weill Cornell Medical College, New York.
Klara LenartLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Marcilio Jorge FumagalliLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Colin KovasMaple Leaf Medical Clinic, Toronto, Ontario, Canada.
R Brad JonesInfectious Diseases Division, Department of Medicine, Weill Cornell Medical College, New York.
Michel NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Frauke MueckschDepartment of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York.
Guinevere Q LeeInfectious Diseases Division, Department of Medicine, Weill Cornell Medical College, New York.ORCID 0000-0002-9412-886X

Funding

REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
Center for Structural Biology of HIV RNAU54AI170660 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALICE TELESNITSKY · 2022 to 2026
$32.1M
Characterization of Non-subtype B HIV-1 Reservoirs and its Association with Longitudinal Clinical OutcomesR01AI162221 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEE, GUINEVERE · 2021 to 2025
$2.1M
Insights into the dynamics of clonal expansion of genome-intact proviruses by examining longitudinal evolution of HIV proviral DNA compositionsR21AI150398 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEE, GUINEVERE · 2020 to 2021
$466k
NIAID NIH HHS R01 AI162221NIAID NIH HHS R21 AI150398NIAID NIH HHS U54 AI170660NIAID NIH HHS UM1 AI164565
6 · The paper itself

Abstract

Retroviral integration into host genomes is central to both HIV-1 persistence and the safety and function of lentiviral vectors used in gene and cell therapies. However, existing integration site assays remain limited by sensitivity, input requirements, and analytical complexity, and none have been validated at the single-molecule detection limit. Here, we introduce PRISM-seq, an ultra-sensitive workflow for genome-wide recovery of lentiviral-host junctions, paired with BulkIntSiteR, an open-source, fully automated pipeline for integration site annotation. We show that PRISM-seq accurately identifies proviral insertions across diverse genomic contexts, including euchromatin, heterochromatin, and repeat-rich centromeric regions, and detects high-confidence integration events down to a single input template molecule. By systematically characterizing assay- and amplification-associated noise, we developed a five-step quality control framework that removes PCR- and sequencing-derived artifacts. PRISM-seq also enables quantitative clonal tracking through replicate-based sampling and achieves performance comparable to or exceeding high-input assays at substantially reduced cost.

Identifiers

PMID41509385
PMCPMC12776086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.